Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 52, 2018 - Issue 5-6
Journal homepage
447
Views
9
CrossRef citations to date
0
Altmetric
Articles

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist

E. David CrawfordDivision of Urology, University of Colorado, Aurora, CO, USA; View further author information
,
B. TombalService d’Urologie, Institut de Recherche clinique (IREC), Cliniques universitaires Saint Luc, Av. Hippocrates, Bruxelles, Belgium; View further author information
,
T. KeaneMedical University of South Carolina, Charleston, SC, USA; View further author information
,
F. BoccardoUniversity of Genoa and Ospedale Policlinico San Martino-IRCCS for Oncology, Genoa, Italy; View further author information
,
K. MillerDepartment of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany; View further author information
,
N. ShoreCarolina Urologic Research Center, Myrtle Beach, SC, USA; View further author information
,
J. W. MoulDivision of Urologic Surgery, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA; View further author information
,
J.-E. DamberUniversity of Gothenburg, Gothenburg, Sweden; View further author information
,
L. ColletteDepartment of Statistics, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; View further author information
&
B.-E. PerssonLäkarhuset, Uppsala, SwedenCorrespondence[email protected]
View further author information
 show all
Pages 349-357 | Received 01 Mar 2018, Accepted 06 Sep 2018, Published online: 09 Jan 2019

References

  • Crawford ED, Shore ND, Moul JW, et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014;83:1122–1128.
  • Hoare D, Skinner TA, Black A, et al. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. Cuaj. 2015;9:122–127.
  • Porter AT. FACRO, Ben-Josef E. Humoral mechanisms in prostate cancer: A role for FSH. Urol Oncol. 2001;6:131–138.
  • Oduwole O, Poliandri A, Rawson P, et al. FSH supplementation increases the growth of PC-3 human prostate cancer cell xenograft in gonadotropin-suppressed nude mice. Endocr Abstr 2016;41:GP117. DOI:10.1530/endoabs.41.GP117.
  • Mariani S, Salvatori L, Basciani S, et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol. 2006;175:2072–2077.
  • Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010; 363:1621–1630.
  • Gittelman M, Pommerville PJ, Persson BE, et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 2008;180:1986–1992.
  • Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805–813.
  • Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–1538.
  • Beer TM, Garzotto M, Eilers KM, et al. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology. 2004;63:342–347.
  • McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58:756–761.
  • Garnick MB, Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. 2012;110:499–504.
  • Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186:889–897.
  • Rick FG, Block NL, Schally AV. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. OncoTargets Ther. 2013;6:391–402.
  • Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomized clinical trials of degarelix versus luteinizing hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–1108.
  • Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57:836–842.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.